Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Novartis ends ALS program after phase 2 flop, adding to R&D woes
(19h)
Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
(21h)
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
(1d)
FDA launches pilot program to speed up sluggish phase 1 trials
(1d)
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
(1d)
Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure
(1d)
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
(1d)
Newly formed Jaguar acquires Afib device assets from JJ
(1d)
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
(2d)
GSK doubles down on Chimagen with $750M multiple myeloma wager
(2d)
BioPharma Dive
Novartis to pay $125M for blood-brain barrier crossing platform
(13h)
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
(18h)
Sling banks $123M for an experimental thyroid eye disease pill
(18h)
Skyhawk racks up more support for Huntington’s drug
(20h)
FDA clears first generic radioligand drug; Sionna turns to layoffs
(1d)
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
(1d)
FDA launches pilot program to speed up early US drug research
(1d)
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
(2d)
AstraZeneca’s newly approved pill fails frontline breast cancer study
(2d)
Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing
(2d)
Endpoints News
Drugmakers cooperate with House probe of China trial sites
(15h)
FDA faces questions on 'America First' provisions in latest user fee agreement
(16h)
Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO
(18h)
Researchers implant human neurons in mice brains to study disease
(18h)
Novo signs Anthropic deal to test Claude Science in RD
(19h)
Novartis' TREM2 drug fails Phase 2 ALS trial
(22h)
Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
(22h)
Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial
(22h)
Klomp, Warren spar over MFN deal contracts
(1d)
FDA approves first radioligand generic, setting up rivalry with Novartis
(1d)
BioSpace
Biopharma hiring hotspots: States, disciplines where demand is highest
(2h)
Trending: Top biopharma disciplines with jobs live now
(2h)
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
(19h)
Deep dive: Psychedelics back on FDA’s doorstep
(19h)
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
(20h)
Sling catches $123M series C for thyroid eye disease pill
(21h)
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
(23h)
AI is changing the talent biotech companies compete to hire
(1d)
For many, the retirement goal posts are shifting
(1d)
5 biotechs braving the commercial waters with product launches
(1d)
STAT News
The FDA’s rebuilding effort is running into a new challenge
(1h)
What happened to oppositional defiant disorder?
(1h)
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
(2h)
New lawsuit argues NIH violated First Amendment rights of grant applicants
(9h)
GOP aims to change Medicare adviser’s math to help out private insurers
(13h)
Senators highlight the power Chris Klomp wields at confirmation hearings
(14h)
WHO expresses cautious optimism about bid to control Ebola outbreak in DRC
(17h)
Scientists made mice with half a brain. Then they filled them with human organoids
(18h)
Sen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding them
(20h)
We’re reading about faster FDA approvals, access to experimental drugs in Montana, and more
(20h)
BioPharma Trend
The Bigger Point Beyond Insilico's Aging Research Milestone
(1w)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(1w)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(2w)
Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome
(2w)
Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms
(4w)
Seven HealthTech Trends In Europe To Watch
(2mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(3mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(3mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(4mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(5mo)
Drug Channels
Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(2d)
Informa Connect’s Pharma/Biotech GTN Summit
(3d)
Drug Channels Leadership Forum 2027: Antonio Ciaccia to Serve as Moderator
(1w)
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
(2w)
The Private Label Biosimilar Paradox in Medicare Part D
(2w)
Medicare, Medicaid, and Reverification: What Patient Support Programs Need to Know Before January 2027
(3w)
Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Drivers, Impact on Coverage from the IRA, and a Drug Price Adventure
(3w)
Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes
(4w)
REMS Removed: Why CAR-T’s Expansion into Community Oncology Could Benefit the Big Three Wholesalers
(4w)
Hub Transitions Need Proven Plans, Smart Scale-Up
(1mo)
European Biotechnology Magazine
SLAS Journals Spotlight AI in Drug Discovery
(2h)
Sensorion files confidentially for potential U.S. IPO
(18h)
The Strüngmann legacy, passed on
(1d)
3PBIOVIAN Appoints Ponchi Kantt-Neaz as Global Executive Business Director
(1d)
ResoTher heart data clear acquisition hurdle, set up 200-patient trial
(1d)
GSK returns to Chimagen for up to $750M myeloma trispecific
(1d)
Agomab’s IPF drug clears first patient test
(2d)
MaaT’s bid to overturn microbiome approval refusal suffers setback
(2d)
Axoltis ALS drug misses Phase 2 endpoint
(2d)
Cellectis scraps CAR-T pipeline in gene editing pivot
(2d)
Drug Hunter
enpatoran (M5049)
(19h)
pociredir
(1d)
How Pyridazinones Mimic Amides, Phenols, and Nicotinamides
(2d)
Lessons from Recently Approved Oral Small Molecules: Dose Regimens, PK, and Safety
(5d)
MK-1088
(5d)
diranersen
(6d)
TNG456
(1w)
EFMC Medicinal Chemistry 2026 First Time Disclosures
(1w)
Covalent Warhead Reactivity Cheat Sheet
(2w)
iberdomide (CC-220)
(2w)
Labiotech.EU
Oncology biotech news: key moves to watch in September 2026
(21h)
New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?
(1d)
BIOSPAIN 2026: Spain’s flagship biotech event is going annual
(2d)
Beyond Ozempic: the GLP-1 landscape in 2026
(2d)
NLS Days 2026: what’s dealmaking like in the Nordics?
(5d)
Rewriting the rules of genetic medicine with tRNA therapeutics
(6d)
Preclinical Pulse: The research catching our eye in September 2026
(1w)
Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next
(1w)
Streamlining stable cell line development from the start
(1w)
When every treatment counts: How clinical trials are changing the outlook for non-Hodgkin lymphoma patients
(1w)
Bio IT World
A 1970s Lipid-Lowering Compound May Offer a New Approach to Obesity
(1d)
Lehigh Team Uses Digital Twin of Gut-Brain Axis to Advance Neurostimulation Therapies
(2d)
What It Takes to Make Generative AI Fit for GMP
(6d)
Ultima, NVIDIA, Google Partner on Pangenome-Aware Whole Genome Sequencing
(1w)
Clearing the Bench-To-Bedside Hurdle: Why Translational Medicine Needs to Start Earlier
(2w)
NVIDIA Acquires Hugging Face for $12.93 Billion
(2w)
Deep-Learning Tool Uses Long-Read Sequencing to Detect Cancer Mutations
(2w)
Trends from the Trenches: Rethinking Computational Workflows for Modern Genomics
(2w)
What Scientists Actually Need From AI
(3w)
Follow the Money: Biological Foundation Models, Automated Bioanalysis, Predictive Cancer Care
(3w)
GEN News
Brain Protein in Mice Offers Insights Into Brain Development and ADHD
(13h)
Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection
(14h)
Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01
(15h)
Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration
(15h)
Red Light Supercharges Anti-Obesity Drug Precursor
(17h)
Choice of Excipients Dramatically Affects Antibody Solubility
(17h)
Lifecycle Approach Could Solve CGT Scale-Up Challenges
(17h)
Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s
(1d)
Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles
(1d)
Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies
(1d)
Cure Today
Gentle Exercises to Keep You Moving During Cancer Treatment feat. Jennifer Tipton
(11h)
Imfinzi Plus Chemotherapy Raises 3-Year Survival to 69% in Gastric Cancer
(16h)
Childhood Leukemia Survivor Shares Her Experience With ALL, Relapse and CAR-T
(1d)
Echoes of the Battle: Navigating Post Cancer Trauma
(1d)
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
(1d)
After His Daughter’s Cancer Treatment, AJ Wyman Realized He Needed Help, Too
(1d)
A Gift from the Sea
(1d)
Enhertu Delays Progression in HER2-Mutant Lung Cancer in Phase 3 Trial
(2d)
3 Trials Advancing Treatment Options for AML and MDS
(2d)
Tagrisso Shows 8-Year Survival Benefit in EGFR-Mutated Lung Cancer
(2d)
Contract Pharma
Gilead Partners With Pan American Health Organization on Lenacapavir Access for Latin America, Caribbean
(14h)
Thermo Fisher Launches SuperScript V Reverse Transcriptase
(14h)
Lilly TuneLab, Twist Bioscience Partner on Antibody Drug Discovery - contractpharma.com
(17h)
Piramal Pharma Plans Solar Power Plant in UK
(18h)
Hovione Doubles US Spray-Drying Capacity With Opening of New NJ Facility
(18h)
Shilpa Biologicals, SPIMACO Bio Ink MENA Biosimilars Deal
(20h)
Sanofi, UCB, Opella Join Clean Heat Program
(20h)
Ori Biotech Lands 10-Year, $120M Commercial Cell Therapy Manufacturing Deal
(1d)
CDMO Capacity: Stainless by Volume, Single-Use by Number
(1d)
Axiom, GeneFab Partner to Advance Therapeutic Pipeline
(1d)
Pharma Times
Jemperli accepted for priority review by US FDA
(2w)
Carterra supports AI‑designed protein study with HT-SPR platforms
(2w)
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
(3w)
Avulux gains FDA authorisation for migraine light‑sensitivity lens
(3w)
Leqembi Iqlik launches in US for early Alzheimer’s
(3w)
Lundbeck gains EU orphan status for anti‑ACTH antibody
(3w)
AC Immune reports positive phase 1 data for ACI‑19764
(3w)
VarmX begins global phase 3 trial of VMX C001
(3w)
VarmX begins global phase 3 trial for VMX C001
(3w)
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
(3w)
Medcity News
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
(15h)
As MA Denial Rates Rise, Hospitals Are Betting on Traditional Medicare Instead
(17h)
AI Isn’t a Therapist, but Many Teens Are Treating It Like One
(19h)
Hospital Margins Fell This Summer Amid Outpatient Slowdown, Data Shows
(1d)
Thatch Secures $108M, Reaches $1B Valuation
(1d)
GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma
(1d)
The Real Bottleneck in U.S. Pharma Reshoring Isn’t Factories – It’s Talent
(1d)
How Human-Led AI Improves Healthcare Marketing Intelligence
(1d)
Nara Health Secures $14M for Third Party Administration Platform
(2d)
Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease
(2d)
Chemical & Engineering News
Why the Reflecting Pool coating peeled and blistered
(12h)
What did a group of Priestly Medalists have to say about the future of chemistry?
(18h)
Comment: Building stronger local sections for the future
(20h)
Editorial: We can have both prosperity and sustainability
(23h)
Groups cite huge health costs from EPA’s power plant GHG rollback, vow to sue
(1d)
Skeletal editing can transform molecules’ biological activity
(1d)
Business Watch: European pyrolysis plants get new owners, and more
(1d)
Custom genetic codes can now be created with ease
(1d)
Periodic Graphics: How do friction-erasable pens work?
(1d)
Learn something
(1d)
The Pharma Letter
Boehringer halts Phase III kidney trial of vicadrostat/Jardiance combination
(49m)
ICER releases evidence report on treatment for Parkinson’s disease
(16h)
Vivan and Ad Atomica pair tumor genotype data with AI drug design
(16h)
Sling Therapeutics announces $123M financing
(19h)
Top-20 Novartis shareholder demands board shake-up after back-to-back trial failures
(19h)
Remepy welcomes new CMO to advance hybrid drug pipeline
(19h)
FDA unveils expedited IND pilot, begins accepting applications
(22h)
Lundbeck wins Japanese approval for Vyepti
(22h)
LB Pharma hires Susan Kozauer as CMO
(22h)
Lundbeck wins Japanese approval for Vyepti
(22h)
Targeted Oncology
After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data
(12h)
Tam-Peli Extends Survival in Relapsed Small Cell Lung Cancer
(15h)
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
(17h)
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
(18h)
Rib-Sparing Approach Lowers Post Thoracotomy Pain
(19h)
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
(20h)
T-DXd Significantly Improves PFS in First-Line HER2-Mutant NSCLC
(1d)
Gotistobart Nearly Doubles Median OS vs Docetaxel in Squamous NSCLC
(1d)
FDA Approves Lutetium Lu 177 Dotatate Injection for SSTR-Positive GEP-NETs
(1d)
Integrating Frontline Biomarkers and Multidisciplinary Teams in Prostate Cancer
(1d)
MedWatch
Lundbeck Foundation secures more votes through share exchange
(27m)
New CEO appointment eases strategy concerns at Bavarian Nordic, Jefferies says
(28m)
Bavarian Nordic names new CEO
(48m)
Ascendis faces financial setback after patent dispute – Yet the CEO sees the outcome as a victory
(3h)
WSA chair supports call for new CFO to have IPO experience: Nevertheless says it's not decisive
(20h)
Scandinavian Medical Solutions' CEO steps down as part executive reshuffle
(20h)
Novo forms partnership with Anthropic
(21h)
WSA recruits new CFO from Novo
(21h)
Abacus aims to double its Polish acquisition: Growth must now be more profitable
(22h)
Ascendis CEO after scrapped Novo partnership: Big mistake to be dependent on Big Pharma
(22h)
In The Pipeline
The ACS Redesign
(1d)
Not The Glue They Thought It Was
(2d)
The State of AI Antibody Design
(5d)
Phosphorylate and Spare Not
(6d)
More Impossible-to-Ignore Vaccine Effects
(1w)
GLP-1 Drugs for Aging?
(2w)
Mutate 'Em All and See If You Can Sort 'Em Out
(2w)
Crappy Antibodies, Made Superficially More Appealing
(2w)
The Alleged Dimethylmercury Incident
(2w)
On vacation until August 31
(3w)
Pharmaphorum
NICE finally backs Enhertu for HER2-low breast cancer
(35m)
Novo taps Anthropic's Claude AI for drug discovery
(1h)
Wales takes UK lead on needle-free anaphylaxis prevention
(17h)
Legend Biotech names ex-Novartis exec as CEO
(20h)
TikTok parent ByteDance raises cash for drug AI spinout Anew
(21h)
AI spots drugs that may be repurposed for priority pathogen
(22h)
FDA unveils framework for its expedited IND pilot
(23h)
FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'
(1d)
Electra sets terms for IPO, hoping to raise up to $347m
(1d)
GSK wagers $750m on Chimagen multiple myeloma therapy
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(3mo)
Therapy enables 89% survival rate in myeloma patients
(3mo)
Ulcerative colitis treatment shows best-in-class potential
(3mo)
UK patients to benefit from approval of weight loss tablet
(3mo)
Vertex presents new data on Casgevy in children
(3mo)
DDW Highlights: 16 June 2026
(3mo)
LXR inverse agonist shows promise in liver disease
(3mo)
Guide: One solution – from R&D, to QC
(3mo)
HIT Consultant
M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care
(15h)
Biohacking’s Gender Problem: Why Women’s Health Protocols Require Dedicated Research and Clinical Variables
(18h)
R1 Unveils Phare Utilization Management on Phare OS to Eliminate Medical Necessity Denials
(18h)
M&A: MRO Acquires Vyne Medical to Expand Intelligent Healthcare Intake Automation
(20h)
FDA Awards Cognita Imaging $1.29M to Validate LLM-as-a-Jury Evaluation Across 1 Million Radiology Reports
(20h)
Cedar Gate Survey Reveals 83% of Health Plans Miss VBC Outcomes Due to Fragmented Data
(22h)
Rutgers, RWJBarnabas Health, and AWS Launch Innovation Hub at HELIX
(22h)
Healthcare’s Cyber Playbook Was Built for Another Era. Here’s How Leaders Can Adapt
(23h)
MEDITECH Completes Expanse Implementation Across 34 Hospitals in HCA Healthcare’s First Two U.S. Divisions
(1d)
Thatch Reaches $1 Billion Unicorn Valuation with $108M Raise to Expand Personalized Health Benefits
(1d)
Insights: Pink Sheet
No Letup In Aging Japan’s Rising Health, Drug Costs
(6h)
OTC Industry Makes First PDUFA Appearance After Months of Behind-the-Scenes Negotiations
(9h)
Big Pharma CEOs Bullish On US Policy Environment Heading Into Midterm Elections
(11h)
PDUFA VIII’s ‘America First’ Fee Incentives Could Be Gamed, Stakeholders Warn US FDA
(13h)
FDA Nominee Heidi Overton Could Appear Before Senate Panel As Soon As Sept. 24
(13h)
EMA Backing Unlikely For MaaT’s Microbiota Therapy After Negative Trend Vote
(16h)
Orphan Drug Hopefuls Navepegritide And Norucholic Acid Face EMA Oral Explanations
(18h)
Zealand’s Glepaglutide Faces Crucial EMA Hearing After US Setback
(18h)
HHS Nominee Klomp Faces Democratic Gauntlet On MFN Deals’ Secrecy, Vaccines At Hearing
(1d)
Gene-Silencing Therapies Face Different Bar Under US FDA Plausible Mechanism Framework
(1d)
BioXconomy
FDA to boost overseas trial site inspections amid concerns about regulatory oversight capacity
(12h)
RegCell banks $66m to advance Nobel-winning immune tolerance platform
(17h)
Japan’s hybrid DCT approach shaped by unique regulations, healthcare system, and geography
(18h)
GSK bets up to $750m on Chimagen's multiple myeloma treatment
(23h)
Shennon lands $12m and new CEO to drive immunotherapy pipeline forward
(1d)
Transcript in the machine: How AI paved the way for customized mRNA cancer treatments
(1d)
How mRNA could change the battle against tuberculosis
(2d)
Peptide therapy triumphs in Phase I Parkinson’s trials
(2d)
Eyes on Asia: Solstice, Gan & Lee, NeuShen Therapeutics
(2d)
nPhase launches AI platform to speed regulatory submissions for clinical trials
(2d)
BioCentury
Academic deals stay close to home
(9h)
Science Spotlight: A macrophage-recruiting bispecific, plus new tactics against TCR-T escape and tumor stroma
(12h)
Sleep deals cluster in narcolepsy and sleep apnea
(13h)
FDA fills in blanks on expedited IND pilot
(1d)
Novartis commercial leader Ingrid Zhang named Legend CEO
(1d)
FDA signals tighter scrutiny of early-stage data from China
(1d)
Lazard’s Gluckman: Annual survey hints at ‘change in architecture’ across industry
(2d)
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
(2d)
AZ’s camizestrant miss narrows oral SERD treatment settings
(2d)
Suppressor tRNAs take two translational steps forward
(2d)
SCRIP
Roivant’s Push To Become More Than A Pipeline Story
(47m)
Amgen Confident In Cardiometabolic Pipeline After Novartis’s Negative Lp(a) Readout
(11h)
Novartis’s VHB937 Latest To Join ALS Clinical Development Graveyard
(12h)
Big Pharma CEOs Outline US Policy Goals Heading Into Midterm Elections
(13h)
Sling Raises $123m As It Takes Oral TED Drug Contender Into Phase III
(16h)
Pfizer CEO Warns China May Follow US To Limit Biotech Deals
(17h)
The Challenges Facing New Chiesi CEO Khougazian
(19h)
Senlang/Tempest Option Marks China’s First Global Deal For In Vivo CAR-T
(1d)
WCLC 2026: Leads Eyes Phase III For Novel Bispecific After Promising 1L NSCLC Data
(1d)
Arrowhead Tackles Two Targets To Lower Multiple ASCVD-Causing Lipids
(1d)